Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP

Executive Director, Biosafety Services, Advarra

Latest Posts by Daniel Eisenman

A decorative image for Regulatory Considerations Document for mRNA Research
Blog

mRNA Clinical Trials: Key Regulatory Considerations

Over the past two years, Operation Warp Speed brought mRNA-based vaccines into the spotlight, as...

Read More...
Blog

Does This Study Require IBC Review?

Gene therapy research is highly regulated due to associated risks, often leading to confusion among...

Read More...
Blog

mRNA and Its Role in Clinical Research

In the race to address the COVID-19 pandemic, researchers have worked tirelessly the past year...

Read More...
Blog

Does Warp Speed Vaccine Development and Testing Compromise Safety?

A common trope in sci-fi movies involves concerns about potentially smashing into uncharted objects while...

Read More...
Blog

Q&A – Study Startup Success for the New Generation of Genetically Engineered Vaccines

In a recent webinar, Advarra Executive Director of Biosafety Services Daniel Eisenman discussed the latest...

Read More...

Q&A Part 1 – Gene Therapy Research in the Age of COVID-19

In Advarra’s inaugural virtual symposium, experts from industry and academia met to discuss the unique...

Read More...

Q&A Part 2 – Gene Therapy Research in the Age of COVID-19

In Advarra’s inaugural virtual symposium, industry and academic experts discussed overcoming obstacles and optimizing study...

Read More...

Safety Precautions for Laboratory Research With COVID-19 Specimens

The current global pandemic has brought biosafety to the spotlight. Biosafety practices must be customized...

Read More...

Infection Control and Biosafety in Gene Therapy Research

Gene therapy research has moved from the realm of science fiction to mainstream clinical research....

Read More...

Planning Gene Therapy Research? Plan for IBC Review

The completion of the human genome project and advances in genetic engineering have paved the...

Read More...
Login
Scroll to Top